Researchers at The University of Queensland (UQ) have announced a potential breakthrough in the search for treatments for Motor Neurone Disease (MND), identifying a new drug target that could lead to therapies capable of slowing the debilitating condition.

An international research team, led by UQ, has developed a novel drug, R8Y, which successfully targets a previously difficult-to-engage immune receptor known as C5aR2. For the first time, scientists have uncovered the receptor's molecular structure, providing critical insights into how inflammation could be managed in neurodegenerative diseases, including MND, Parkinson's disease, and Alzheimer's disease.

Professor Trent Woodruff, a lead researcher on the project, expressed optimism that the findings could significantly alter the outlook for future patients. "With this knowledge, it's possible we could have an anti-inflammatory drug treatment for testing in MND patients within 5 years, possibly turning the disease into a long-term chronic condition rather than an acute terminal illness," Woodruff stated.

The team's new drug, R8Y, binds specifically to C5aR2, allowing researchers to observe its structure and function. This revealed that C5aR2 does not interact with G proteins in the typical way, which had previously made it a challenging target and contributed to the elusiveness of its role in inflammation. The research used R8Y to create a model of the drug bound to the receptor, yielding vital information on how the drug interacts and how the receptor signals.

Professor Trent Woodruff hopes their world-first discovery could eventually turn Motor Neurone Disease into a manageable long-term chronic condition for patients

Building on these findings, UQ researchers are now focused on developing improved anti-inflammatory drugs tailored for challenging neurodegenerative diseases. Associate Professor Richard Clark highlighted the importance of international collaboration, involving researchers from Australia, Japan, South Korea, India, and Europe, in achieving this breakthrough. "This global effort demonstrates the power of cross-disciplinary and cross-border collaboration in tackling complex biomedical challenges," Clark said. "With this new ability to selectively target the C5aR2 receptor, we can develop safer, more effective drugs with fewer side effects."

The announcement offers a glimmer of hope for individuals like former NRL player Jai Arrow, who was diagnosed with MND at 30 and forced to retire. The rugby league community has rallied behind Arrow, launching the 'Jai July' campaign to raise funds and awareness for MND. Arrow has been seeking specialized treatment in Spain.

Arrow continues fighting MND as researchers edge closer to treatments that could slow the devastating neurological disease significantly

MND has affected other prominent Australian sports figures. Former Queensland State of Origin player Carl Webb was diagnosed with MND in 2020 and became an advocate before his death in December 2023. In Australian Rules football, former Essendon player and Melbourne coach Neale Daniher, diagnosed in 2014, became a leading figure in MND awareness and research funding through his FightMND foundation before his passing in May.

Carl Webb's legacy lives on as researchers continue searching for better treatments to combat the devastating effects of Motor Neurone Disease

Neale Daniher's tireless FightMND campaign helped drive awareness as scientists edge closer to another major breakthrough for patients everywhere

This research breakthrough follows the recent launch of Australia's first unified national database for Amyotrophic Lateral Sclerosis (ALS), the most common form of MND. This database, which combines clinical information and biological samples from over 1,300 Australian patients, aims to accelerate diagnosis, clinical trials, and the development of future treatments.